T1	Claim 1652 1722	Patients reported similar pain and satisfaction scores in both groups.
T2	Claim 1723 1878	Bolus IV administration of G-CSF results in longer neutropenia duration than SC administration, with no difference in clinical or quality-of-life measures.
T3	Premise 1069 1253	The mean time to neutropenia resolution was longer with IV G-CSF [7.9 days, 95% confidence interval (CI) 6.6-9.1] compared with SC G-CSF (5.4 days, 95% CI 4.6-6.2), log-rank P = 0.001.
T4	Premise 1254 1320	Longer neutropenia duration was observed in all patient subgroups,
T5	Premise 1321 1367	except for patients undergoing autologous HCT.
R1	Partial-Attack Arg1:T5 Arg2:T4	
T6	Premise 1368 1459	There was no significant difference between groups in the occurrence of infection or death,
T7	Premise 1460 1564	but more deaths were observed with IV (4/57, 7%) versus SC (1/61, 1.6%) G-CSF administration, P = 0.196.
R2	Partial-Attack Arg1:T7 Arg2:T6	
R3	Support Arg1:T4 Arg2:T2	
R4	Support Arg1:T3 Arg2:T2	
R5	Support Arg1:T1 Arg2:T2	
